Nutriband Inc（NTRB）股票分析NTRBNutriband Inc

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Nutriband Inc is currently not a strong buy due to its recent performance and financial instability. The current price is $4.46, and the company has a negative forward P/E of 370.37, indicating significant valuation concerns. Additionally, the gross margin has dropped to 22.20% in the latest quarter, which is concerning for profitability. The main risk is the high negative net income, which was -24,814,503 USD in Q2 2026, reflecting ongoing financial struggles.